The global antibody production market is experiencing significant growth, driven by increasing prevalence of cancer and autoimmune disorders. The market size is projected to reach US$ 30.7 billion by 2031, driven by the demand for monoclonal antibodies (mAbs) for targeted treatments and the rising need for tailored therapies.
Kerala is on high alert after a 14-year-old boy tested positive for the Nipah virus in Malappuram district. The state is taking precautionary measures, including mask mandates in public spaces and isolation of high-risk contacts, as it awaits the arrival of monoclonal antibodies. The virus, which can be transmitted from animals to humans or between humans, has caused several outbreaks in Kerala in recent years.
Nipah virus, a deadly infection of the brain, has no licensed treatment or vaccine. However, a recent study has presented a potential game-changer for future treatment options. Scientists compared the effectiveness of two different monoclonal antibodies against Nipah virus, and the results showed that a new antibody, hu1F5, was highly effective in protecting African green monkeys from the virus. This study provides promise for potential future testing of the hu1F5 monoclonal antibody in humans and highlights the importance of continued research in the fight against emerging infectious diseases.
